| Basics |
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
|
| IPO Date: |
August 23, 1999 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$112.67M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.16 | 3.61%
|
| Avg Daily Range (30 D): |
$0.07 | 3.72%
|
| Avg Daily Range (90 D): |
$0.08 | 3.53%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.87M |
| Avg Daily Volume (30 D): |
1.76M |
| Avg Daily Volume (90 D): |
1.36M |
| Trade Size |
| Avg Trade Size (Sh.): |
268 |
| Avg Trade Size (Sh.) (30 D): |
258 |
| Avg Trade Size (Sh.) (90 D): |
232 |
| Institutional Trades |
| Total Inst.Trades: |
3,231 |
| Avg Inst. Trade: |
$1.7M |
| Avg Inst. Trade (30 D): |
$.96M |
| Avg Inst. Trade (90 D): |
$1.03M |
| Avg Inst. Trade Volume: |
.02M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.58M |
| Avg Closing Trade (30 D): |
$1.67M |
| Avg Closing Trade (90 D): |
$1.45M |
| Avg Closing Volume: |
49.21K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-2.72
|
$-.87
|
$-.61
|
|
Diluted EPS
|
$-2.72
|
$-.87
|
$-.61
|
|
Revenue
|
$ .18M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -108.09M
|
$ -45.5M
|
$ -23.52M
|
|
Operating Income / Loss
|
$ -89.72M
|
$ -21.21M
|
$ -23.08M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 14.88M
|
$ 12.22M
|
$ -15.56M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jan 25, 2024:
1:12
|
|
Jun 09, 2014:
1:4
|
|
Jun 06, 2014:
1:4
|
|
Sep 13, 2004:
1:4
|
|
|
|
